2025-03-31 18:39:20
Latest Post
NHPC commissions 3 units of Parbati-II HE project
ixigo announces APRIL FULL REFUND SALE for 1st April - 100 Lucky Travellers To Win 100% Refund on Flight Bookings
Engineers India Ltd receives orders worth Rs. 245 crores
Blue Star appoints Mohit Sud as Group President, Unitary Cooling Products 
Jyoti Ltd receives Rs. 108.17 crores IT demand notice for AY 2020-21
Stock Report
Bliss GVS Pharma Ltd Q4 FY2023 consolidated net profit falls to Rs. 3.34 crore
Posted On : 2023-05-11 23:10:25( TIMEZONE : IST )
Bliss GVS Pharma Limited has reported Consolidated financial results for the period ended March 31, 2023.
Financial Results (Q4 FY2023) - QoQ Comparison
The company has reported total income of Rs. 187.7569 crores during the period ended March 31, 2023 as compared to Rs. 211.3635 crores during the period ended December 31, 2022.
The company has posted net profit / (loss) of Rs. 3.3438 crores for the period ended March 31, 2023 as against net profit / (loss) of Rs. 27.9419 crores for the period ended December 31, 2022.
The company has reported EPS of Rs. 0.33 for the period ended March 31, 2023 as compared to Rs. 2.64 for the period ended December 31, 2022.
| Financials | Q4 FY2023 | Q3 FY2023 | % Change |
| Total Income | ₹187.7569 crs | ₹211.3635 crs |  -11.17% |
| Net Profit | ₹3.3438 crs | ₹27.9419 crs | -88.03% |
| EPS | ₹0.33 | ₹2.64 | -87.50% |
Financial Results (Q4 FY2023) - YoY Comparison
The company has reported total income of Rs.187.7569 crores during the period ended March 31, 2023 as compared to Rs.179.2518 crores during the period ended March 31, 2022.
The company has posted net profit / (loss) of Rs.3.3438 crores for the period ended March 31, 2023 as against net profit / (loss) of Rs.19.6320 crores for the period ended March 31, 2022.
The company has reported EPS of Rs.0.33 for the period ended March 31, 2023 as compared to Rs.1.87 for the period ended March 31, 2022.
| Financials | Q4 FY2023 | Q4 FY2022 | % Change |
| Total Income | ₹187.7569 crs | ₹179.2518 crs |  4.74% |
| Net Profit | ₹3.3438 crs | ₹19.6320 crs | -82.97% |
| EPS | ₹0.33 | ₹1.87 | -82.35% |
Financial Results (Year Ended FY2023) - YoY Comparison
The company has reported total income of Rs.769.3739 crores during the Financial Year ended March 31, 2023 as compared to Rs.778.9460 crores during the Financial Year ended March 31, 2022.
The company has posted net profit / (loss) of Rs.70.8588 crores for the Financial Year ended March 31, 2023 as against net profit / (loss) of Rs.15.0402 crores for the Financial Year ended March 31, 2022.
The company has reported EPS of Rs.6.72 for the Financial Year ended March 31, 2023 as compared to Rs.1.43 for the Financial Year ended March 31, 2022.
| Financials | Year Ended FY2023 | Year Ended FY2022 | % Change |
| Total Income | ₹769.3739 crs | ₹778.9460 crs | -1.23% |
| Net Profit | ₹70.8588 crs | ₹15.0402 crs | 371.13% |
| EPS | ₹6.72 | ₹1.43 | 369.93% |
Shares of Bliss GVS Pharma Limited was last trading in BSE at Rs. 83.76 as compared to the previous close of Rs. 82.18. The total number of shares traded during the day was 47799 in over 657 trades.
The stock hit an intraday high of Rs. 87.22 and intraday low of 80.55. The net turnover during the day was Rs. 4010496.00.
